Primary bone and soft tissue tumors are uncommon tumors, which originate from bone, cartilage, muscle, fiber, fat, synovium, and other mesenchymal tissues. Some patients have high degree of malignancy, poor treatment effects and prognosis, while some patients can achieve good curative effect by complete surgical resection. Due to a delayed diagnosis and lack of understanding of the disease, many patients still have a low five-year survival rate. Bone and soft tissue tumors should be paid enough attention. Single cell sequencing has advanced sarcoma and bone metastatic disease research. Regulatory T cells, macrophage, tissue resident memory T cells and etc. are found to be closely associated with bone and soft tissue tumors progression and metastasis. In the era of targeted therapy, increasing small molecule drugs, such as TKIs, are expected to conquer sarcomas. In addition, bioengineering-based therapies, such as CART and TCRT, are promising. A great number of researches in ferroptosis, autophagy, oxidative stress, exosome, organoid, tumor infiltrating lymphocyte, and mitochondria damage have greatly updated our understanding of molecular mechanisms underlying bone and soft tissue tumors.
This Research Topic aims to promote our understanding of primary bone and soft tissue tumors as well as bone metastasis, including molecular mechanisms, RNA sequencing, targeted therapy, biomarkers for early diagnosis, big-data driven clinical decision, and personalized medicine. We receive original articles, review articles, brief reports, letter to editor and etc.
We welcome submissions covering, but not limited to, the following aspects:
1. Novel mechanisms, including ferroptosis, autophagy, oxidative stress, exosome, organoid, tumor infiltrating lymphocyte, and mitochondria damage, for primary bone and soft tissue tumors as well as bone metastasis.
2. Small-molecule inhibitors for primary and metastatic bone tumors.
3. Surgical innovations for bone tumors, especially pelvic and spinal tumors. Risk factors, preventative measures, therapeutics for bone metastasis, especially spinal metastasis, and skeletal related events (SREs). Cohort studies or clinical trials exploring novel diagnostic/prognostic factors.
4. Next-generation sequencing application, such as WGS, genomics, proteomics, and metabonomics in bone metastasis and primary bone and soft tissue tumors.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Primary bone and soft tissue tumors are uncommon tumors, which originate from bone, cartilage, muscle, fiber, fat, synovium, and other mesenchymal tissues. Some patients have high degree of malignancy, poor treatment effects and prognosis, while some patients can achieve good curative effect by complete surgical resection. Due to a delayed diagnosis and lack of understanding of the disease, many patients still have a low five-year survival rate. Bone and soft tissue tumors should be paid enough attention. Single cell sequencing has advanced sarcoma and bone metastatic disease research. Regulatory T cells, macrophage, tissue resident memory T cells and etc. are found to be closely associated with bone and soft tissue tumors progression and metastasis. In the era of targeted therapy, increasing small molecule drugs, such as TKIs, are expected to conquer sarcomas. In addition, bioengineering-based therapies, such as CART and TCRT, are promising. A great number of researches in ferroptosis, autophagy, oxidative stress, exosome, organoid, tumor infiltrating lymphocyte, and mitochondria damage have greatly updated our understanding of molecular mechanisms underlying bone and soft tissue tumors.
This Research Topic aims to promote our understanding of primary bone and soft tissue tumors as well as bone metastasis, including molecular mechanisms, RNA sequencing, targeted therapy, biomarkers for early diagnosis, big-data driven clinical decision, and personalized medicine. We receive original articles, review articles, brief reports, letter to editor and etc.
We welcome submissions covering, but not limited to, the following aspects:
1. Novel mechanisms, including ferroptosis, autophagy, oxidative stress, exosome, organoid, tumor infiltrating lymphocyte, and mitochondria damage, for primary bone and soft tissue tumors as well as bone metastasis.
2. Small-molecule inhibitors for primary and metastatic bone tumors.
3. Surgical innovations for bone tumors, especially pelvic and spinal tumors. Risk factors, preventative measures, therapeutics for bone metastasis, especially spinal metastasis, and skeletal related events (SREs). Cohort studies or clinical trials exploring novel diagnostic/prognostic factors.
4. Next-generation sequencing application, such as WGS, genomics, proteomics, and metabonomics in bone metastasis and primary bone and soft tissue tumors.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
